How to Cite
Abstract
Cholangiocarcinoma (CC) is the second most common malignant disease of the liver. In recent decades various methods of treatment have been introduced. Nevertheless the number of treatment options for СС is still limited. Gemcitabine and cisplatin are the standard treatment for patients with inoperable CC. The second line of chemotherapy has not yet been standardized and depends on the interaction with first-line therapy. In addition many bile cancer studies to date cannot evaluate the differential activity of therapy of different anatomical localizations along the bile tract. There is no reliable evidence of the effectiveness of adjuvant therapy. The correlation of survival increase in patients with worse prognosis when using adjuvant therapy after surgical intervention seems to be reliable. The study of the molecular profile led to a more complex understanding of the genetic changes leading to clinically expressed malignant neoplasms and the possible future differentiation by anatomical or molecular structure would be optimal for the selection of chemotherapy.References
Бредер В.В. Рак желчевыводящей системы // Практическая онкология. - 2012. - Т. 13. - 4(52). - С. 269-275.
Патютко Ю.И., Поляков А.Н., Котельников А.Г., и др. Хирургическое и комбинированное лечение больных с опухолью Клацкина // Хирургия. - 2014. - № 10. - С. 25-32.
Alvaro D., Crocetti E., Ferretti S., et al. Descriptive epidemiology of cholangiocarcinoma in Italy // Dig Liver Dis. - 2010. - Vol. 42(7). - P 490-495. - 10.1016/j. dld.2009.10.009. DOI: 10.1016/j.dld.2009.10.009
Andersen J.B., Spee B., Blechacz B.R., et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors // Gastroenterology. - 2012. - Vol. 142(4). - P 1021-1031. - e15. - 10.1053/j. gastro.2011.12.005. DOI: 10.1053/j.gastro.2011.12.005
Bekaii-Saab T., Phelps M.A., Li X., et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers // J. Clin. Oncol. - 2011. - Vol. 29(17). - P 2357-2363. - 10.1200/ JCO.2010.33.9473. DOI: 10.1200/JCO.2010.33.9473
Bengala C., Bertolini F., Malavasi N., et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial // Br. J. Cancer. - 2010. - Vol. 102(1). - P 68 72. - DOI: 10.1038/sj.bjc.6605458
Ben-Josef E., Guthrie K.A., El-Khoueiry A.B., et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma // J. Clin. Oncol. - 2015. - Vol. 33(24). - P 2617-2622. - doi: 10.1200ДIШ.2014.60.2219.
Brieau B., Dahan L., De Rycke Y., et al. Second-line chemotherapy for advanced biliary tract Cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Ent rologues Oncologues // Cancer. - 2015. - Vol. 121(18). - P. 3290-3297. - DOI: 10.1002/cncr.29471
Cho J.Y., Paik Y.H., Chang Y.S., et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma // Cancer. - 2005. - Vol. 104(12). - P 2753-2758.
Ducreux M., Rougier P., Fandi A., et al. Effective treatment of advanced biliary tract carcinoma using 5-fluoro-uracil continuous infusion with cisplatin // Ann Oncol. - 1998. - 9(6). - P. 653-656.
Eckel F., Brunner T., Jelic S.; ESMO Guidelines Working Group. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. - 2011. - 22(Suppl 6). - P vi40-44. - 10.1093/ annonc/mdr375. DOI: 10.1093/annonc/mdr375
El-Khoueiry A.B., Rankin C., Siegel A.B., et al. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma // Br. J. Cancer. - 2014. - Vol. 110(4). - P. 882887. - DOI: 10.1038/bjc.2013.801
El-Khoueiry A.B., Rankin C.J., Ben-Josef E., et al. SWOG 0514: a phase II study of sorafenib in patients with unre-sectable or metastatic gallbladder carcinoma and cholangiocarcinoma // Invest New Drugs. - 2012. - Vol. 30(4). - P 1646-1651. - DOI: 10.1007/s10637-011-9719-0
Farley D.R., Weaver A.L., Nagorney D.M. «Natural history» of unresected cholangiocarcinoma: patient outcome after noncurative intervention // Mayo Clin. Proc. - 1995. - №70. - P. 425-429.
Glazer E.S., Liu P., Abdalla E.K., et al. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins // J. Gastrointest. Surg. - 2012. - Vol. 16(9). - P. 16661671. - DOI: 10.1007/s11605-012-1935-1
Goyal L., Zheng H., Yurgelun M.B. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma // Cancer. - 2017. - Vol. 123(11). - P. 1979-1988. - DOI: 10.1002/cncr.30571
Graham J.S., Boyd K., Coxon F.Y., et al. A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract // BMC Res Notes. - 2016. - №9. - P. 161. - DOI: 10.1186/s13104-015-1778-4
Gruenberger B., Schueller J., Heubrandtner U., et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study // Lancet Oncol. - 2010. - Vol. 11(12). - P. 1142-1148. - DOI: 10.1016/S1470-2045(10)70247-3
Halim A., Ebrahim M.A., Saleh Y. A phase II study of outpatient biweekly gemcitabine-oxaliplatin in advanced biliary tract carcinomas // Jpn J. Clin. Oncol. - 2011. - Vol. 41(2). - P. 217-224. - DOI: 10.1093/jjco/hyq207
Hong Y.S., Lee J., Lee S.C., et al. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer // Cancer Chemother Pharmacol. - 2007. - Vol. 60(3). - P. 321-328.
Kim H.J., Lee N.S., Lee S.C., et al. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer // Cancer Chemother Pharmacol. - 2009. - Vol. 64(2). - P. 371-377. - DOI: 10.1007/s00280-008-0883-7
Kim K.P., Jang G., Hong Y.S., et al. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity // Br. J. Cancer. - 2011. - Vol. 104(4). - P. 605-612. - DOI: 10.1038/bjc.2011.17
Kim T.W., Chang H.M., Kang H.J. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer // Ann Oncol. - 2003. - Vol. 14(7). - P. 1115-1120.
Knox J.J., Hedley D., Oza A., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial // J. Clin. Oncol. - 2005. - Vol. 23(10). - P. 2332-2338.
Lamarca A., Hubner R.A., David Ryder W., Valle J.W. Second-line chemotherapy in advanced biliary cancer: a systematic review // Ann Oncol. - 2014. - Vol. 25(12). - P. 2328-2338. - DOI: 10.1093/annonc/mdu162
Lee J., Park S.H., Chang H.M., et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study // Lancet Oncol. - 2012. - Vol. 13(2). - P. 181188. - 10.1016/S 1470-2045(11)70301-1. DOI: 10.1016/S1470-2045
Lee J.K., Capanu M., O'Reilly E.M., et al. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas // Br. J. Cancer. - 2013. - Vol. 109(4). - P. 915-919. - DOI: 10.1038/bjc.2013.432
Li H., Zhang Z.Y., Zhou Z.Q., et al. Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.// Oncotarget. - 2016. - 7(18). - P. 26888-26897. DOI: 10.18632/oncotarget.8590
McNamara M.G., Walter T., Horgan A.M., et al. Outcome of adjuvant therapy in biliary tract cancers // Am J. Clin. Oncol. - 2015. - Vol. 38(4). - P. 382-387. - DOI: 10.1097/COC.0b013e31829e19fb
Moehler M., Maderer A., Schimanski C., et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme // Eur. J. Cancer. - 2014. - Vol. 50(18). - P. 3125-3135. - 10.1016/j. ejca.2014.09.013. DOI: 10.1016/j.ejca.2014.09.013
Murakami Y., Uemura K., Sudo T., et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma // Ann Surg. Oncol. - 2011. - Vol. 18(3). - P. 651-658. - 10.1245/ s10434-010-1325-4. DOI: 10.1245/s10434-010-1325-4
Novarino A.M., Satolli M.A., Chiappino I., et al. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer // Am J. Clin. Oncol. - 2013. - Vol. 36(5). - P. 466-471. - 10.1097/œC.0b013e31825691c3. DOI: 10.1097/?C.0b013e31825691c3
Oh S.Y., Jeong C.Y., Hong S.C., et al. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness // Invest New Drugs. - 2011. - Vol. 29(5). - P.1066-1072. - DOI: 10.1007/s10637-010-9417-3
Okusaka T., Nakachi K., Fukutomi A., et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan // Br. J. Cancer. - 2010. - Vol. 103(4). - P. 469-474. - DOI: 10.1038/sj.bjc.6605779
Pant S., Saleh M., Bendell J., et al. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors // Ann Oncol. - 2014. - Vol. 25(7). - P. 14161421. - DOI: 10.1093/annonc/mdu157
Petrioli R., Roviello G., Fiaschi A.I., et al. Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer // Anticancer Drugs. - 2015. - Vol. 26(6). - P. 682-686. - DOI: 10.1097/CAD.0000000000000233
Plentz R.R., Malek N.P. Systemic Therapy of Cholangio-carcinoma // Visc Med. - 2016. - 32(6). - P. 427430. - DOI: 10.1159/000453084
Santoro A., Gebbia V., Pressiani T., et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study // Ann Oncol. - 2015. - Vol. 26(3). - P. 542-547. - DOI: 10.1093/an-nonc/mdu576
Sasaki T., Isayama H., Nakai Y., et al. A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer // Cancer Chemother Pharmacol. - 2013. - Vol. 71(4). - P. 973-979. - DOI: 10.1007/s00280-013-2090-4
Sasaki T., Isayama H., Nakai Y., et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine // Invest New Drugs. - 2012. - Vol. 30(2). - P. 708713. - DOI: 10.1007/s10637-010-9553-9
Shaib Y.H., Davila J.A., McGlynn K., El-Serag H.B. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? // J. Hepatol. - 2004. - Vol. 40(3). - P. 472-477.
Suzuki E., Ikeda M., Okusaka T., et al. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer // Cancer Chemother Pharmacol. - 2013. - Vol. 71(5). - P. 1141-1146. - DOI: 10.1007/s00280-013-2106-0
Taïeb J., Mitry E., Boige V., et al. Optimization of 5-fluo-rouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma // Ann Oncol. - 2002. - Vol. 13(8). - P. 1192-1196.
Valle J.W., Wasan H., Johnson P., et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study -The UK ABC-01 Study // Br. J. Cancer. - 2009. - Vol. 101(4). - P. 621-627. - DOI: 10.1038/sj.bjc.6605211
Valle J.W., Wasan H., Lopes A., et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial // Lancet Oncol. -2015. - Vol. 16(8). - P. 967-978. - 10.1016/ S1470-2045(15)00139-4. DOI: 10.1016/S1470-2045
Voss J.S., Holtegaard L.M., Kerr S.E., et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions // Hum Pathol. - 2013. - Vol. 44(7). - P. 1216-1222. - 10.1016/j. humpath.2012.11.006. DOI: 10.1016/j.humpath.2012.11.006
Wang Y., Li J., Xia Y., et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy // J. Clin. Oncol. - 2013. - Vol. 31(9). - P. 11881195. - DOI: 10.1200/JCO.2012.41.5984
West J., Wood H., Logan R.F., et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001// Br. J. Cancer. - 2006. - Vo. 94(11). - P. 1751-1758.
Yamashita Y., Taketomi A., Itoh S., et al. Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers // Jpn J. Clin. Oncol. - 2010. - Vol. 40(1). -P. 24-28. - DOI: 10.1093/jjco/hyp119
Yang H., Zhou J., Wei X., et al. Survival outcomes and progonostic factors of extrahepatic cholangiocarcinoma patients following surgical resection: Adjuvant therapy is a favorable prognostic factor // Mol. Clin. Oncol. - 2014. - Vol. 2(6). - P. 1069-1075. - 10.3892/ mco.2014.377. DOI: 10.3892/mco.2014.377
Yang X., Wang W., Wang C., et al. Characterization of EGFR family gene aberrations in cholangiocarcinoma // Oncol Rep. - 2014. - Vol. 32(2). - P. 700-708. - DOI: 10.3892/or.2014.3261
Yi J.H., Thongprasert S., Lee J., et al. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study // Eur. J. Cancer. - 2012. - Vol. 48(2). - P. 196-201. - DOI: 10.1016/j.ejca.2011.11.017
Yoshikawa D., Ojima H., Iwasaki M., et al. Clinicopatho-logical and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma // Br. J. Cancer. - 2008. - Vol. 98 (2). - P. 418-425. - DOI: 10.1038/sj.bjc.6604129
Yusuf M.A., Kapoor V.K., Kamel R.R., et al. Modification and implementation of NCCN guidelines on hepatobiliary cancers in the Middle East and North Africa region // J. Natl. Compr. Canc. Netw. - 2010. - Vol. 8 (Suppl 3). - P. S36-40.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018